Mawer Investment Management Ltd. raised its position in Novartis AG (NYSE:NVS) by 3.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,758,166 shares of the company’s stock after purchasing an additional 92,908 shares during the period. Novartis accounts for about 1.9% of Mawer Investment Management Ltd.’s portfolio, making the stock its 15th largest position. Mawer Investment Management Ltd.’s holdings in Novartis were worth $231,576,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NVS. Wealthcare Advisory Partners LLC purchased a new position in Novartis in the third quarter valued at $106,000. Cable Hill Partners LLC grew its position in shares of Novartis by 588.8% in the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after purchasing an additional 1,107 shares during the period. Calton & Associates Inc. acquired a new stake in shares of Novartis in the fourth quarter valued at about $118,000. SeaCrest Wealth Management LLC acquired a new stake in shares of Novartis in the fourth quarter valued at about $124,000. Finally, Trustcore Financial Services LLC acquired a new stake in shares of Novartis in the fourth quarter valued at about $178,000. 10.96% of the stock is owned by institutional investors.
Several analysts have recently issued reports on NVS shares. Zacks Investment Research upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Leerink Swann lifted their target price on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, October 31st. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, UBS Group reiterated a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and an average price target of $85.32.
Novartis (NYSE:NVS) last posted its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.04. The firm had revenue of $12.92 billion for the quarter, compared to analyst estimates of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. Novartis’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 earnings per share. analysts anticipate that Novartis AG will post 5.36 EPS for the current fiscal year.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.